Dr. Davila’s bibliography includes high-impact articles in Science Advances, Nature, International Journal of Hematology, The Lancet, and New England Journal of Medicine.
Recent publications
Faramand RG, et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 2024 Jan 9;. [Epub ahead of print]
Boucher JC, S et al. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics. 2023 Dec 19;31:100751.
Rejeski K, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep 22;9(38):eadg3919.
Dong N, et al. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8.
Lee DH, et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr 1;9(1):18.
Stein-Thoeringer CK, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 Apr;29(4):906-916.
Holtan SG, et al. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality. Clin Cancer Res. 2023 Mar 14;29(6):1114-1124.
Sallman DA, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023 Mar;10(3):e191-e202.
Boucher JC, et al. Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. J Immunother. 2023 Jan 1;46(1):5-13.
Connect with the Davila Lab
Email Dr. DavilaConnect on LinkedIn
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263